Generic metformin pills, which treat Type 2 diabetes. Photo: Francis Dean/Corbis via Getty Images

Walgreens and three other pharmacy chains are suing drugmaker Bausch Health, its subsidiaries and a separate generic drugmaker for allegedly colluding on a deal that allowed the brand-name companies to maintain a longer monopoly of the diabetes drug Glumetza. The alleged deal resulted in those companies jacking up the price of the drug from $350 to more than $3,000 for a 30-day supply.

Why it matters: When combined with similar lawsuits from employer groups, the suing parties are looking to recoup more than $10 billion in overcharges from this antitrust case — another in a long line of infamous "pay-for-delay" deals over generic drugs. Bausch has said it intends "to vigorously defend these matters."

Go deeper: Read the lawsuit.

Go deeper

Dion Rabouin, author of Markets
2 hours ago - Economy & Business

Bond investors see brighter days

Illustration: Sarah Grillo/Axios

U.S. government bonds could breakout further after yields on the benchmark 10-year Treasury note ticked up to their highest since early June last week.

But, but, but: Strategists say this move is about an improving outlook for economic growth rather than just inflation.

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Politics: The swing states where the pandemic is raging. Ex-FDA chief: Pence campaigning after COVID exposure puts others at risk — Mark Meadows: "We are not going to control the pandemic"
  2. Health: 13 states set single-day coronavirus case records last week — U.S. reports over 80,000 new cases for second consecutive day.
  3. Education: The dangerous instability of school re-openings.
  4. World: Australian city to exit one of world's longest lockdowns — In photos: Coronavirus restrictions grow across Europe
  5. Media: Fox News president and several hosts advised to quarantine after possible COVID-19 exposure
  6. Nonprofit: Rockefeller Foundation commits $1 billion for COVID-19 recovery
Erica Pandey, author of @Work
3 hours ago - Economy & Business

The dangerous instability of school re-openings

Illustration: Eniola Odetunde/Axios

Schools across the country have flip-flopped between in-person and remote learning — and that instability is taking a toll on students' ability to learn and their mental health.

The big picture: While companies were able to set long timelines for their return, schools — under immense political and social strain — had to rush to figure out how to reopen. The cobbled-together approach has hurt students, parents and teachers alike.